Asimov launched its AAV Edge Stable Producer system, offering clonal HEK293 producer cell lines that integrate essential viral genes to enable high‑titer, stable AAV manufacture without repeated GMP plasmid transfection. The company claims titers up to 6E15 vg/L before purification and a delivery timeline for research cell banks of roughly 20 weeks. Asimov framed the technology as an answer to transient transfection bottlenecks—reducing cost, supply-chain risk and batch variability while facilitating scale‑up. The offering targets sponsors seeking more consistent, scalable AAV supply for clinical and commercial programs. Stable producer cell lines could materially lower manufacturing costs and improve process control for gene therapies, a critical constraint as developers move toward broader indications and larger patient populations.